Clinical Trial

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-11; most recent amendment 2025-12-22.
Trial Details
NCT Number NCT06368921
Lead Sponsor Guangzhou Virotech Pharmaceutical Co., Ltd.
Conditions Solid Tumor
Enrollment 30 participants
Start Date 2024-06-19
Primary Completion 2026-09 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-30